Swiss National Bank Sells 1,900 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Swiss National Bank trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 74,500 shares of the company’s stock after selling 1,900 shares during the period. Swiss National Bank owned 0.16% of Amphastar Pharmaceuticals worth $2,160,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of AMPH. PNC Financial Services Group Inc. raised its position in shares of Amphastar Pharmaceuticals by 13.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,783 shares of the company’s stock valued at $139,000 after buying an additional 580 shares in the last quarter. Arkadios Wealth Advisors raised its position in shares of Amphastar Pharmaceuticals by 21.5% during the 1st quarter. Arkadios Wealth Advisors now owns 33,966 shares of the company’s stock valued at $985,000 after buying an additional 6,002 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Amphastar Pharmaceuticals during the 1st quarter valued at $532,000. GSA Capital Partners LLP raised its position in shares of Amphastar Pharmaceuticals by 159.8% during the 1st quarter. GSA Capital Partners LLP now owns 45,297 shares of the company’s stock valued at $1,313,000 after buying an additional 27,863 shares in the last quarter. Finally, Picton Mahoney Asset Management raised its position in shares of Amphastar Pharmaceuticals by 6,600.0% during the 1st quarter. Picton Mahoney Asset Management now owns 1,608 shares of the company’s stock valued at $46,000 after buying an additional 1,584 shares in the last quarter. 65.09% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AMPH. Wells Fargo & Company decreased their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Needham & Company LLC upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research report on Tuesday, August 12th. Piper Sandler decreased their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research report on Friday, August 8th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $31.50.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock opened at $30.50 on Friday. The firm has a market cap of $1.42 billion, a PE ratio of 11.42 and a beta of 0.76. Amphastar Pharmaceuticals, Inc. has a 12-month low of $20.39 and a 12-month high of $53.96. The company has a quick ratio of 2.21, a current ratio of 3.29 and a debt-to-equity ratio of 0.80. The company’s fifty day simple moving average is $24.10 and its two-hundred day simple moving average is $25.82.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.